English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu
“Value & Outcomes Spotlight is excited to work with Biogen to promote novel approaches for previously intractable neurodegenerative conditions such as Alzheimer’s disease,” said Zeba M. Khan, RPh, PhD, Editor-in-Chief. “This collaborative project directly aligns with our vision to see Value & Outcomes Spotlight develop a wider presence and attract a broader audience of scholars, payers, industry, and other stakeholders,” added Laura T. Pizzi, PharmD, MPH, Editor-in-Chief.
The supplement opens with 2 editorials. The first by Eric Jutkowitz, PhD, Brown University School of Public Health, Providence, RI, USA, and Joseph Gaugler, PhD, School of Public Health, University of Minnesota, Minneapolis, MN, USA, introduces some of the unique challenges of valuing treatments for Alzheimer’s disease. The second by Paola Barbarino, MA, CEO of Alzheimer’s Disease International, London, England, UK, calls to all stakeholders to collaborate and invest in dementia responses as the economic and social costs of inaction are colossal.
The remaining 3 articles in the supplement provide detailed value assessment perspectives from leading experts in Alzheimer’s disease research:
- “Defining Elements of Value in Alzheimer’s Disease,” by Garrison, et al, the authors propose that funders should evaluate the value of an Alzheimer’s disease and related dementias intervention from a wide perspective and draw on the “value flower” as an evaluation framework.
- “Value Assessment in Alzheimer’s Disease: A Focus on Equity,” by Basu, et al, applies the lens of health equity, focusing on the brain equity considerations within a value framework and suggesting the use of an equity-efficacy impact plane to evaluate interventions for Alzheimer’s disease and related dementias.
- “Long-Term Value Demonstration in Alzheimer’s Disease: Evidence Needs,” by Barbarino, et al, considers the need for long-term value demonstration by identifying data gaps that must be addressed.
“Driven by our commitment to patients, Biogen remains focused on furthering Alzheimer’s disease research and treatment,” said Robin P. Thompson, PhD, Senior Director, Value and Access, Biogen. “We appreciate the opportunity to collaborate with ISPOR on this important project. The topics discussed in this supplement and the associated webinars are critical as stakeholders work together to improve care, research, and the development of new treatments, and, most importantly, ensure that all people and families affected by dementia receive the support they need.”
Visit ISPOR.org to view the entire webinar series, which included the following presentations: (1) Valuing Future Alzheimer’s Disease Medicines: Extending the Paradigm; (2) Value Assessment in Alzheimer’s Disease: A Focus on Equity; and (3) Long Term Value Demonstration in Alzheimer’s Disease: Evidence Needs.
Visit Biogen.com to learn more about its Alzheimer’s disease investigational candidates and clinical trials.
###
ABOUT ISPOR
ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Website | LinkedIn | Twitter (@ispororg) | YouTube | Facebook | Instagram
ABOUT VALUE & OUTCOMES SPOTLIGHT
Value & Outcomes Spotlight is ISPOR’s bimonthly news publication for the global HEOR community that provides feature articles on timely HEOR topics, methodological and health policy articles, as well as updates from ISPOR leadership and news from around the world.
Website | Twitter (@isporjournals)
